6533b828fe1ef96bd1288ea0

RESEARCH PRODUCT

Borderline resectable pancreatic cancer. Challenges and controversies.

Dimitri DorcarattoAntonio DarderSusana RosellóLuis SabaterAndrés CervantesMarina Garcés-albirMaría Del Carmen Gómez-mateoMarisol HuertaAntonio Ferrández-izquierdoElena MuñozDesamparados Roda

subject

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentGeneral surgeryGeneral MedicineDisease030230 surgerymedicine.diseasePancreatic Neoplasms03 medical and health sciences0302 clinical medicineOncologyNeoadjuvant treatmentBorderline resectable030220 oncology & carcinogenesisPancreatic cancerPreoperative CaremedicineCurative surgeryHumansRadiology Nuclear Medicine and imagingbusinessNeoadjuvant therapy

description

Abstract Pancreatic cancer is a dismal disease with an increasing incidence. Despite the majority of patients are not candidates for curative surgery, a subgroup of patients classified as borderline resectable pancreatic cancer can be selected in whom a sequential strategy of neoadjuvant therapy followed by surgery can provide better outcomes. Multidisciplinary approach and surgical pancreatic expertise are essential for successfully treating these patients. However, the lack of consensual definitions and therapies make the results of studies very difficult to interpret and hard to be implemented in some settings. In this article, we review the challenges of borderline resectable pancreatic cancer, the complexity of its management and controversies and point out where further research and international cooperation for a consensus strategy is urgently needed.

10.1016/j.ctrv.2018.06.006https://pubmed.ncbi.nlm.nih.gov/29957372